Vinayak Muralidhar Selected Research

Prostatic Neoplasms (Prostate Cancer)

1/2023	Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality.
1/2022	Racial disparities in treatment delay among younger men with prostate cancer.
1/2022	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
1/2022	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
7/2021	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?
1/2021	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
1/2021	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
1/2021	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer.
1/2021	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer.
11/2020	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vinayak Muralidhar Research Topics

Disease

48	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 07/2015
34	Neoplasms (Cancer) 01/2022 - 01/2015
4	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2018
2	Adenocarcinoma 10/2021 - 07/2015
1	Breast Neoplasms (Breast Cancer) 01/2023
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 05/2021
1	Second Primary Neoplasms (Neoplasms, Second) 01/2021
1	Anus Neoplasms (Anal Cancer) 12/2020
1	COVID-19 10/2020
1	Ovarian Neoplasms (Ovarian Cancer) 01/2020

Drug/Important Bio-Agent (IBA)

17	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 11/2015
14	AndrogensIBA 01/2021 - 11/2015
2	Hormones (Hormone)IBA 01/2017 - 10/2016
1	AntigensIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 11/2021
1	GenieIBA 11/2021
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Protons (Proton)IBA 01/2020
1	Biological FactorsIBA 01/2017
1	EnzymesIBA 12/2015
1	Pyruvate KinaseIBA 01/2015
1	Protein Isoforms (Isoforms)IBA 01/2015

Therapy/Procedure

30	Radiotherapy 01/2023 - 01/2016
23	Therapeutics 01/2021 - 11/2015
17	Prostatectomy (Retropubic Prostatectomy) 01/2021 - 07/2015
13	Brachytherapy 01/2021 - 07/2015
2	Conservative Treatment 10/2019 - 12/2017
1	Treatment Delay 01/2022
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2021
1	Immunotherapy 12/2020
1	Castration 11/2020
1	Re-Irradiation 04/2017
1	Proton Therapy 01/2016